New Insights into Kidney Transplantation
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".
Deadline for manuscript submissions: 23 January 2025 | Viewed by 924
Special Issue Editor
Special Issue Information
Dear Colleagues,
In this Special Issue, we present a collection of articles exploring the forefront of kidney transplantation. This Special Issue discusses the latest advancements in immunosuppressive therapies, including new drug developments and strategies to enhance patient outcomes and long-term management. We examine the breakthroughs in genomics and biomarkers that are transforming the early detection and personalized treatment of transplant rejection. The Special Issue will extend to the application of artificial intelligence and machine learning in kidney transplantation, highlighting their role in optimizing post-transplant care. Furthermore, this Special Issue covers innovative surgical techniques such as optimization of ogran utilization and preservation and minimally invasive and robotic-assisted procedures that are advancing recovery and reducing complications. Collectively, these articles offer a comprehensive overview of the pioneering efforts in kidney transplant care. They provide valuable perspectives for healthcare professionals and researchers dedicated to improving patient outcomes and addressing the critical challenges of organ shortages.
Dr. Sami Alasfar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- rejection
- organ optimization
- transplantation
- immunosuppressants
- biomarkers
- AI
- innovation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Immunosuppression in Kidney Transplant Recipients: Current Status and Future Directions
Authors: Muhammad A. Khan; Bassam G. Abu Jawdeh
Affiliation: Mayo Clinic Arizona, Division of Nephrology and Hypertension
Abstract: Kidney transplantation is the gold standard treatment for patients with end-stage kidney disease. Despite the ongoing gap between organ availability and demand, it is inevitable that kidney transplantation will continue to grow. This is owed to broader organ sharing, increased comfort of transplant programs with marginal kidney utilization and the expansion of paired exchange among living donor kidneys. The evolution of kidney transplantation could not have been possible without the availability of effective immunosuppressive regimens that maintain graft function. Mycophenolate and calcineurin inhibitors continue to constitute the backbone of modern maintenance immunosuppression. Despite remarkably improving acute rejection rates, long-term outcomes with these regimens remain suboptimal. Alternative immunosuppressives such as belatacept and mammalian _target of rapamycin inhibitors have been promising, however their wider-scale adoption as first line therapies remains delayed due to concerns about increased rejection rates. In addition to continuing the investigation of steroid and calcineurin inhibitor sparing protocols, it is prudent to identify practical, measurable surrogates to long-term graft survival. Herein, we review current immunosuppressive regimens, discuss challenges and future directions.
Highlights: 1-Mycophenolate and calcineurin inhibitors continue to constitute the backbone of modern maintenance immunosuppression in kidney transplantation. 2-Belatacept, a novel immunosuppressive biologic has a favorable safety profile, however, its wider adoption has been impeded by concerns about early rejection. 3-Efforts should continue to identify effective immunosuppressive regimens with a favorable adverse event profile.
